

All sessions are in Mountain Time

**Session Days and Time are Provisional** 

# Saturday, March 1, 2025

<u>6:30 AM – 7:00 AM</u> Breakfast with the Vendors

<u>7:00 AM – 9:30 AM</u> Session Name: Digital (modeling and ai) - Instrumentation, AI and Data Analysis in Nuclear Session Chair: Hans Vija Co-Chair: Nicolas Karakatsanis, PhD

Presentations:

Topic 1: Ultra-performance total-body PET multi-parametric imaging to monitor human physiology and diseases Speaker: Nicolas A Karakatsanis, PhD

Topic 2: Multi-modality Synergistic Imaging in Nuclear Medicine Speaker: Andreas Kjaer, MD, PhD

*Topic 3: Quantitative PET and SPECT Image Reconstruction powered by Artificial Intelligence Speaker: Chi Liu, PhD* 

*Topic 4: The advent of Digital Twins and Personalized Radiation Therapy with Dosimetry Speaker: Arman Rahmim, PhD* 

*Topic 5: Data Utilization for Nuclear Medicine Theranostics and Necessity for Standardization Speaker: Julia Brosch-Lenz, PhD* 

Topic 6: Round-Table Discussion with Q&A Speakers: All session moderators and speakers

<u>1:00 PM – 3:00 PM</u> Roundtable: Open Discussion: Prostate & Neuroendocrine Lead: Michael Graham

<u>4:00 PM – 7:30 PM</u> Session Name: Cardiology Session Chair: Piotr Slmoka

### Co-Chair: Panithaya Chareonthaitawee, MD

#### **Presentations:**

Topic 1: Carving New Trails in Cardiac PET: The Evolving Landscape of SPECT and PET MPI Speaker: Mouaz al-Mallah, MD

*Topic 2: Slopes Ahead: Are We Ready for Flurpiridaz and Other New PET Perfusion Tracers? Speaker: Jamieson Burque* 

*Topic 3: Fresh Powder in PET MBF: What's New on the Horizon? Speaker: Panithaya Chareothaitawee, MD* 

*Topic 4: Shredding the Data: AI Insights from PET/CT Attenuation Maps Speaker: Piotr Slomka, PhD* 

*Topic 5: Hitting the Slopes with New PET Tracers for Amyloid Imaging Speaker: Sarah Cuddy, MD* 

#### Sunday, March 2, 2025

# All sessions are in Mountain Time

<u>6:30 AM – 7:00 AM</u> Breakfast with the Vendors

<u>7:00 AM – 9:30 AM</u> Session Name: Pediatric Session Session Chair: Helen Nadel, MD Co-Chair: Alan Packard

Presentations: Latest Developments in Pediatric Nuclear Medicine – Imaging & Therapy

*Topic 1: Monitoring Pediatric Patients with Cancer Predisposition Syndromes with PET Speaker: Helen Nadel, MD* 

*Topic 2: Why are PET and SPECT images essential for pediatric epilepsy evaluation? Speaker: Maria Rosana Ponisio* 

*Topic 3: New Therapeutic Options for Recurrent Neuroblastoma, from small molecules to antibodies Speaker: Alan Packard* 

*Topic 4: Early experience with EFOV PET CT in a pediatric oncology population Speaker: Barry Shulkin, MD* 

*Topic 5: Imaging features of neuroimmunity in autism spectrum disorder with PET-MRI Speaker: Nicole Zurcher, PhD* 

<u>1:00 PM – 3:00 PM</u> Roundtable: SIRT Lead: Michael Wissmeyer

<u>4:30 PM – 6:00 PM</u> Hal O'Brien Rising Star Session Session Chair: Piotr Slomka Co-Chair: Peter Conti

Title:

*Topic 1: Coronary microvascular function and systemic inflammatory disorders: A novel marker of risk Speaker: Brittany Weber, PhD* 

*Topic 2: Advancing Radiopharmaceutical Therapies for Equitable Patient Care Speaker: Carlos Uribe, PhD* 

<u>6:00 PM – 7:00 PM</u>

Past President's Session - Lessons Learned, Perspectives on Future Moderator: Alan Packard Past Presidents: Helen Nadel, MD Peter Conti Michael Graham Alan Packard Richard Wahl, MD, PhD Cathy Cutler, PhD

Top Reasons to attend (topics specific):

- 1. Where the Society was vs Where it is going?
- 2. Where is the future in nuclear medicine?
- 3. How to become the next SNMMI President
- 4. Where are we getting the next generation of Nuclear Medicine Practitioners

<u>7:00 PM – 9:00 PM</u>

## Sunday Night Dinner & Hal O'Brien Rising Star Award Ceremony

Open to all in-person attendees with meeting registration. Additional tickets available for guests.

#### Monday, March 3, 2025

#### All sessions are in Mountain Time

<u>6:30 AM – 7:00 AM</u> Breakfast with the Vendors

7:00 AM – 9:30 AM Session Name: Regulatory Session Chair: Ira Goldman Co-Chair: Cathy Cutler, PhD

**Presentations:** 

Topic 1: SNMMI Government Affairs Activities Speaker: Cathy Cutler, PhD

Topic 2: AI Landscape – From Approval to Reimbursement Speaker: Munir Ghesani

*Topic 3: Radiopharmaceutical Quality: Perspectives on Current Compliance Issues Speaker: Chris Ignace* 

*Topic 4: NRC Rulemaking and Guidance related to Nuclear Medicine Speaker: Daniel Shaw* 

#### <u>1:00 PM – 3:00 PM</u>

Roundtable: Cognitive impairment: Nuclear Medicine in the Patient journey *Lead: Maria Rosana Ponisio* 

<u>4:00 PM – 7:30 PM</u> Session Name: Theranostic including Alpha trials #1 (cutting edge focus / radiobiology) Session Chair: Andreas Kjaer, MD, PhD Co-Chair: Richard Wahl, MD, PhD

#### **Presentations:**

*Topic 1: Radiobiology of alpha and beta emitters: do we understand it? Speaker: Edward O'Neill, PhD* 

*Topic 2: Which alpha emitter to pick: pros and cons beyond availability Speaker: Andreas Kjaer, MD, PhD* 

*Topic 3: Dosimetry in drug development and patient management Speaker: Stephen A Graves, PhD* 

*Topic 4: Radiolabeled monoclonal antibodies as theranostics revisited Speaker: Richard Wahl, MD, PhD* 

*Topic 5: Pretargeting for radiotheranostics Speaker: Andreas Kjaer, MD, PhD* 

#### Tuesday, March 4, 2025

# All sessions are in Mountain Time

<u>6:30 AM – 7:00 AM</u> Breakfast with the Vendors

<u>7:00 AM – 9:30 AM</u> Session Name: Theranostics #2 (clinical trial focus) Session Chair: Richard Wahl, MD, PhD

### Co-Chair: Andreas Kjaer, MD, PhD

## **Presentations:**

*Topic 1: Will We Have Sufficient Alpha and Beta Therapeutic Radionuclides to Meet Demand? Speaker: Roy Brown* 

Topic 2: Targeted Alpha Therapy (TAT) in SSTR expressing neuroendocrine tumors with Pb-212-DOTAMTATE (AlphaMedix ™), in PRRT naïve and progressed settings- The latest Phase II results Speaker: Ebrahim Delpassand, MD

*Topic 3: Initial Clinical Experience with Pb212 VMT alpha NET in patients with Neuroendocrine Tumors: Feasibility, Toxicity, and early Clinical Results Speaker: Vikas Prasad, PhD* 

Topic 4: A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC) presented at ASCO last spring. Speaker: Won Kim

**Topic 5: Panel Discussion** 

<u>1:00 PM – 3:00 PM</u> Roundtable: Dosimetry & post treatment spect Lead: Michael Graham, MD, PhD and Richard Wahl, MD, PhD

<u>4:00 PM – 7:30 PM</u> Session Names: Neurology Session Chair: Andrew Stephens Co-Chair: Neil Vasdev

#### **Presentations:**

*Topic 1: Revised Criteria for Diagnosis and Staging and their clinical implications Speaker: Mary Ellen Koran, MD, PhD* 

Topic 2: Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment Speaker: Renaud La Joie, PhD

*Topic 3: Recent Progress for Imaging Traumatic Brain Injuries Speaker: Carmela Tartaglia, MD* 

*Topic 4: AD: one year after disease modification therapy and its reimbursement Speaker: Ana Franceschi, MD, PhD* 

*Topic 5: Dominantly Inherited Alzheimer's Disease Speaker: Tammy Benzinger, MD, PhD* 

*Topic 6: PET imaging in non-AD neurodegeneration Speaker: Maura Malpetti, PhD*